Guggenheim Maintains Buy on Faeth Therapeutics, Lowers Price Target to $69

Benzinga · 6d ago
Guggenheim analyst Michael Schmidt maintains Faeth Therapeutics (NASDAQ:FTH) with a Buy and lowers the price target from $70 to $69.